Mastering data to turn medicinal product regulations into business value

19 July 2016
darren-cooper-big

In our weekly expert view piece, Darren Cooper, director of industry solutions at Stibo Systems examines the implications and potential benefits of the Indentification and Medicinal Products (IDMP) standards.

As regulations continue to evolve, the pharmaceutical industry is faced with a series of new demands as it manages information to meet increasing challenges.

Designed to support the unique identification and exchange of regulated information, the recent introduction of Identification of Medicinal Products (IDMP) standards could go some way to addressing the ambiguity around how medicines are packaged, marketed, sold, dosed and consumed in different countries.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical